Anti-leukotriene drugs in the prevention and treatment of hepatorenal syndrome

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 68, Issue 4, 2003, Pages 263-265

  Capella, G L ^a  

^a NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; MIDODRINE; MONTELUKAST; ORNIPRESSIN; OZAGREL; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; RAMATROBAN; SERATRODAST; THROMBOXANE RECEPTOR BLOCKING AGENT; ZAFIRLUKAST; ZILEUTON;

ARTICLE; ASCITES; BINDING KINETICS; DRUG METABOLISM; DRUG RESEARCH; HEPATORENAL SYNDROME; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RECEPTOR BINDING; TREATMENT INDICATION;

EID: 0037378250     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(03)00004-8     Document Type: Article

References (19)

1. R. Dagher, K. Moore, The hepatorenal syndrome, Gut 49 (2001) 729-737.
2. P. Angeli, R. Volpin, G. Gerunda, et al., Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide, Hepatology 29 (1999) 1690-1697.
3. F. Wong, L. Blendis, Pathophysiology and treatment of hepatorenal syndrome, Gastroenterologist 6 (1998) 122-135.
4. P. Gentilini, G. Laffi, G. La Villa, et al., Ascites and hepatorenal syndrome during cirrhosis: two entities or the continuation of the same complication?, J. Hepatol. 31 (1999) 1088-1097.
5. D. Mirouze, R.D. Zipser, T.B. Reynolds, Effect of inhibitors of prostaglandin synthesis on induced diuresis in cirrhosis, Hepatology 3 (1983) 50-55.
6. M. Epstein, M. Lifschitz, Renal eicosanoids as determinants of renal function in liver disease, Hepatology 7 (1987) 1359-1367.
7. J.D. Imig, C. Kitiyakara, C.S. Wilcox, in: D.W. Seldin, G. Giebisch (Eds.), Arachidonate metabolism. The Kidney. Physiology and Pathophysiology, 3rd Edition, Lippincott-Williams & Wilkins, Baltimore-New York, 2000, pp. 873-887.
8. 2 and prostacyclin in decompensated liver disease and hepatorenal syndrome, Gastroenterology 100 (1991) 1069-1077.
9. 4 elimination and metabolism in man, J. Allergy Clin. Immunol. 85 (1990) 3-9.
10. K.P. Moore, G.W. Taylor, N.H. Maltby, et al., Increased production of cysteinil leukotrienes in hepatorenal syndrome, J. Hepatol. 11 (1990) 263-271.
11. F. Lang, W. Gerok, D. Haussinger, New clues to the pathophysiology of hepatorenal failure, Clin. Investigator 71 (1993) 93-97.
12. S. Badalamenti, G. Graziani, F. Salerno, et al., Hepatorenal syndrome: new perspectives in pathogenesis and treatment, Arch. Intern. Med. 153 (1993) 1956-1967.
13. A.R. Leff, Discovery of leukotrienes and development of antileukotriene agents, Ann. Allergy Asthma Immunol. 86 (suppl. 1) (2001) 4-8.
14. A.R. Leff, Regulation of leukotrienes in the management of asthma: biology and clinical therapy, Annu. Rev. Med. 52 (2001) 1-14.
15. B. Wedi, A. Kapp, Pathophysiological role of leukotrienes in dermatological diseases: potential therapeutic implications, Biodrugs 15 (2001) 729-743.
16. Physicians' Desk Reference 1999, 53rd Edition, Medical Economics Company, Montvale, NJ, 481-483, 1999, 1886-1899, 3402-3404.
17. J.M. Dogné X. De Leval, P. Benoit, et al., Therapeutic potential of thromboxane inhibitors in asthma, Expert Opin. Invest Drugs 11 (2002) 275-281.
18. J.M. Dogné X. De Leval, J. Delarge, et al., Recent developments of thromboxane modulators, Expert Opin. Ther. Patents 11 (2001) 1663-1675.
19. X. De Leval, F. Julémont, J. Delarge, et al., New trends in dual 5-LOX/COX inhibition, Curr. Med. Chem. 9 (2002) 941-962.